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Introduction
Aminoglycoside antibiotics are invaluable therapeutic agents, but they can cause deafness and, in some 
instances, balance disorders, largely due to the loss of  hair cells from the inner ear (1, 2). Due to their broad 
spectrum and rapid bactericidal activity, they are indicated as part of  empirical therapy for evident or sus-
pected sepsis and other serious infections (3, 4). A major use is in pediatrics, with approximately 80% of  
newborns admitted to neonatal intensive care units being treated with aminoglycosides (5, 6). Their use is 
also increasing due to emerging multidrug-resistant pathogens, e.g., in the treatment of  cystic fibrosis and 
tuberculosis (3, 7). The long-term daily administration of  aminoglycosides required to manage these condi-
tions results in a high incidence of  hearing loss, affecting the quality of  life (8, 9).
Hair cells have a mechanosensory hair bundle located at their apical surface, and there is evidence that 
the aminoglycosides, known to be permeant blockers of  the mechanoelectrical transducer (MET) channels 
in the hair bundle, enter into hair cells via these large-conductance cation channels (10–14). Once inside the 
hair cell, the aminoglycosides cause increases in reactive free radicals and mitochondrial calcium concen-
tration, leading to either apoptosis or necrosis (1, 2, 15). While there are many points at which aminogly-
coside-induced hair cell death could be prevented, blocking ototoxin entry into hair cells may be the most 
effective strategy for protection (10, 16).
Recent studies (16–23) have shown that the lateral line system of  zebrafish larvae is a powerful model 
for discovering compounds that can protect sensory hair cells from the toxic side effects of  aminoglyco-
side antibiotics. At least 24 compounds have been described that protect zebrafish lateral line hair cells, 
some of  which (16, 20, 23) reduce or block the uptake of  Texas red–conjugated gentamicin (GTTR) into 
Aminoglycoside antibiotics are used to treat life-threatening bacterial infections but can cause 
deafness due to hair cell death in the inner ear. Compounds have been described that protect 
zebrafish lateral line hair cells from aminoglycosides, but few are effective in the cochlea. As the 
aminoglycosides interact with several ion channels, including the mechanoelectrical transducer 
(MET) channels by which they can enter hair cells, we screened 160 ion-channel modulators, 
seeking compounds that protect cochlear outer hair cells (OHCs) from aminoglycoside-induced 
death in vitro. Using zebrafish, 72 compounds were identified that either reduced loading of the 
MET-channel blocker FM 1-43FX, decreased Texas red–conjugated neomycin labeling, or reduced 
neomycin-induced hair cell death. After testing these 72 compounds, and 6 structurally similar 
compounds that failed in zebrafish, 13 were found that protected against gentamicin-induced death 
of OHCs in mouse cochlear cultures, 6 of which are permeant blockers of the hair cell MET channel. 
None of these compounds abrogated aminoglycoside antibacterial efficacy. By selecting those 
without adverse effects at high concentrations, 5 emerged as leads for developing pharmaceutical 
otoprotectants to alleviate an increasing clinical problem.
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the neuromast hair cells, while others (16, 19) block the uptake of  both GTTR and FM 1-43, a styryl dye 
that, like the aminoglycoside antibiotics, acts as a permeant blocker of  the hair cell MET channel (24).
Thus far, however, only 4 compounds discovered using zebrafish larvae have been reported to protect 
hair cells of  the mammalian inner ear from aminoglycoside antibiotics (21, 25, 26). Two of  these, tacrine 
and PROTO1, provide protection against aminoglycoside-induced hair cell death in cultures of  the utricular 
maculae of  3- to 6-week-old mice (16, 21). Phenoxybenzamine (25) and berbamine have been shown, respec-
tively, to cause partial and full protection of  OHCs in mouse cochlear cultures against aminoglycosides when 
used at a low concentration. At slightly higher concentrations, however, both can cause OHC death (25, 26).
We therefore sought to identify compounds that would protect mammalian OHCs from aminoglycosides 
and not, either alone or in combination with the antibiotic, cause hair cell death or damage. As the hair cell 
MET channel can be blocked by a variety of  compounds that also block other ion channels (27), a library of  
160 known ion-channel agonists/antagonists (Tocriscreen Custom Collection Ion Channel Set) was screened 
on zebrafish larvae using 3 different assays, seeking compounds that would either block FM 1-43FX dye 
loading, inhibit Texas red–conjugated neomycin (TR-Neo) labeling, or prevent neomycin-induced death of  
hair cells. Compounds effective in any of  these 3 assays, together with a small set of  structurally similar 
compounds from the library, were then tested in mouse cochlear cultures, screening for those that protect 
basal-coil mammalian OHCs from gentamicin, a widely used, clinically relevant aminoglycoside antibiotic.
Results
Preselecting potential otoprotective compounds using zebrafish lateral line neuromasts. Three different screens of  the 
Tocriscreen library were performed on zebrafish larvae at 4 days postfertilization (dpf), a stage that ensures 
reliable loading of  both FM 1-43FX and Yo-Pro-1 into the hair cells of  lateral line neuromasts (28, 29). In 
the first screen, the compounds were tested at a concentration of  100 μM to determine if  they would block 
or reduce the loading of  3 μM FM 1-43FX (Figure 1, A–D, and Supplemental Figure 1, A and B; supple-
mental material available online with this article; https://doi.org/10.1172/jci.insight.96773DS1). In the 
second screen, compounds were assessed at a concentration of  100 μM for their ability to reduce the entry 
of  25 μM TR-Neo into hair cells (Figure 1E and Supplemental Figure 1, C and D). In the third screen, the 
compounds were tested at a concentration of  25 μM for their ability to protect hair cells prelabeled with 
Yo-Pro-1 from damage or death caused by exposure to 6.25 μM neomycin for 1 hour (Figure 1F and Sup-
plemental Figure 1, E–H). Each screen was repeated on 3 independent occasions.
The FM 1-43FX screen identified 37 compounds that showed full or partial block of  dye loading (Fig-
ure 1D), the TR-Neo screen identified 53 compounds that showed complete block or reduction of  labeling 
(Figure 1E), and the neomycin-protection screen identified 43 compounds that either partially or fully pro-
tected hair cells (Figure 1F). One of  the compounds, suramin, provided a positive result in all 3 screens but 
is known to be promiscuous in biological assays (30) and was therefore excluded from the results described 
above and further consideration. One compound, 13228, consistently killed the larvae during the neo-
mycin-protection assay, and it was therefore not possible to assess its potential protective ability. Slowed 
circulation was also detected with this compound in the FM 1-43FX and TR-Neo assays. In total, 72 com-
pounds were positive in 1 of  the 3 assays on at least one trial, and 19 of  these were effective in all 3 assays, 
reducing FM 1-43FX loading, TR-Neo entry, and neomycin-induced cell death.
Retesting compounds from zebrafish screens in mouse cochlear cultures. The 72 compounds identified above, 
along with an additional 6 structurally similar compounds from the library that were negative in all 3 
zebrafish assays, were initially tested in a single trial at a concentration of  50 μM in mouse cochlear cultures 
to see if  they would protect hair cells from exposure to 5 μM gentamicin for 48 hours, a concentration of  
gentamicin sufficient to kill hair cells in the basal third of  the cochlea. Compounds that were generally 
cytotoxic or failed to provide any evidence of  protection at this step were not pursued further. Those that 
improved basal-coil OHC survival in the presence of  gentamicin were subsequently retested on two or 
more independent occasions, with the numbers of  individual cochleae used for each compound ranging 
from 3 to 11. Using this approach, and the criteria described in the Supplemental Methods, 12 protective 
compounds (including 1 of  the 6 selected on the basis of  structural similarity to those that were effective 
in the zebrafish) and 1 partially protective compound were identified (Figure 2, Supplemental Table 1, and 
Supplemental Figure 2). When the concentration was reduced to 10 μM, 3 of  the 13 compounds (13097, 
13143, and 13170) were protective, 6 were partially protective, and 4 provided no protection (Supplemental 
Table 1 and Supplemental Figures 2 and 3).
Downloaded from http://insight.jci.org on January 4, 2018.   https://doi.org/10.1172/jci.insight.96773
3insight.jci.org   https://doi.org/10.1172/jci.insight.96773
R E S E A R C H  A R T I C L E
With 8 of  these 13 compounds that provided protection at 50 μM (13087, 13104, 13142, 13150, 13170, 
13190, 13196, and 13228) varying degrees of  hair-bundle damage were observed in the presence of  genta-
micin (Figure 2). To determine if  any had adverse effects on hair cells in the absence of  gentamicin, they 
were tested alone at concentrations of  50 and 100 μM (Figure 3 and Supplemental Figure 4). At 50 μM, 5 
compounds (13087, 13150, 13170, 13196, and 13228) caused hair-bundle damage (Supplemental Figure 4, 
B, G, I, K, and N). When the concentration was increased to 100 μM, 4 compounds (13087, 13150, 13218, 
and 13228) were generally cytotoxic or caused loss of  the sensory epithelium (Figure 3, B, G, L, and N), 
and a further 4 compounds (13104, 13170, 13190, and 13196) caused hair-bundle damage (Figure 3, D and 
I–K). Of  the 13 compounds, only 5 (13097, 13142, 13143, 13154, and 13222) did not cause hair cell death 
or hair-bundle damage at a concentration of  100 μM.
Two of  the compounds, 13097 and 13143, those that did not cause hair-bundle damage when tested 
alone at 100 μM and also provided protection against 5 μM gentamicin at a concentration of  10 μM, were 
subsequently tested to determine the minimum concentration at which they would protect against 5 μM 
Figure 1. Zebrafish screen. (A) Cranial and trunk neuromasts in a control larva treated with FM 1-43FX and imaged with the Phenosight system, (B) 
a larva in which the compound blocked FM 1-43FX entry into hair cells, and (C) a larva that became fluorescent in which neuromasts could not be 
screened. (D–F) Scatter plots showing all results for each screen. Compounds are grouped according to biological activity. Compounds were given a 
score where 0 = toxic, 1 = no block or no protection, 2 = weak block or partial protection, and 3 = full protection. Each screen was repeated 3 times so 
the pass threshold is >3 (at least 1 screen with a score higher than 1), fail = 3 (3 screens each with a score of 1), and toxic < 3. Colored dots identify 
compounds that protected hair cells in mouse cochlear cultures from gentamicin: green dots identify those that blocked the MET channel, and red 
dots identify those that did not block the MET channel. All larvae were at 4 dpf. Scale bar: 1 mm.
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gentamicin (Figure 4 and Supplemental Table 1). Compound 13143 provided protection down to 1 μM 
(half-protecting concentration K = 840 nM) with a 95% CI of  210–1,480 nM, and compound 13097 was 
effective at concentrations as low as 10 nM, with K = 4.9 nM (95% CI 2.2–7.7 nM).
Effects of  otoprotective compounds on MET-channel currents in mouse OHCs. To determine if  any of  the 13 
compounds that prevented gentamicin-induced hair cell death in cochlear cultures impede antibiotic entry 
via the MET channel, we tested whether they block MET currents in OHCs. Each compound was tested 
at a concentration of  50 μM at membrane potentials ranging from –164 mV to +96 mV. Examples of  MET 
currents recorded before, during, and after exposure to 50 μM of  13143 or 13222 are shown in Figure 5, 
A and B, respectively. MET currents were unaffected during superfusion with 13143 but were reduced 
in amplitude by 13222. This reduction in MET current amplitude caused by 13222 was observed at all 
potentials tested (–164 mV to +96 mV) and was strongest at moderately negative membrane potentials. 
Current-voltage curves derived from the peak MET currents recorded at all membrane potentials before, 
during, and after compound exposure further revealed the lack of  interaction of  13143 with the channel 
(Figure 5C) and the voltage-dependence of  the channel block by 13222 (Figure 5D). The MET currents 
and current-voltage curves also demonstrated that the currents fully recovered following 13222 exposure, 
indicating that the channel block was completely reversible. Of  the 13 compounds tested, 7 had no effect 
on the MET current size across all membrane potentials, indicating a lack of  interaction with the channel 
Figure 2. Compounds providing protection against gentamicin-induced hair cell loss in mouse cochlear cultures. Cochlear cultures from P2 pups 
were treated with either (A) 0.5% DMSO (n = 67), (B) 5 μM gentamicin and 0.5% DMSO (n = 67), or (C–O) 5 μM gentamicin and 50 μM compound (C) 
13087 (n = 5), (D) 13097 (n = 9), (E) 13104 (n = 5), (F) 13142 (n = 8), (G) 13143 (n = 8), (H) 13150 (n = 4), (I) 13154 (n = 5), (J) 13170 (n = 5), (K) 13190 (n = 3), 
(L) 13196 (n = 5), (M) 13218 (n = 10), (N) 13222 (n = 11) and (O) 13228 (n = 4). Cultures were labeled with TRITC-phalloidin, and images were acquired 
from the basal coil. Images in A and B are representative of 67 experiments. Images in C–O are representative of 4–11 experiments. A compound was 
considered protective if it protected in ≥60% of tests. Asterisks identify cultures with damaged hair bundles; arrows indicate specific examples of 
some of the damaged bundles. Scale bar: 50 μm.
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(Figure 5E and Supplemental Table 1). Six of  the thirteen compounds (13087, 13104, 13142, 13154, 13218, 
and 13222) interacted with the MET channel. All but one of  these (13087) provided a maximum block at 
moderately negative membrane potentials (e.g., at –44 mV for 13222) and a partial release of  the block at 
both extreme negative and positive potentials (Figure 5F and Supplemental Table 1). The partial release of  
the block at negative potentials reveals that the compounds are, like dihydrostreptomycin (13) and FM 1-43 
(24), permeant blockers of  the MET channel.
Effects of  otoprotective compounds on K+-channel currents in mouse OHCs. Of  the 13 compounds that protect 
mouse OHCs from gentamicin-induced death, 4 (13087, 13097, 13143, and 13154) are potassium channel 
blockers (31–34). Two of  these are blockers of  KV7 channels (13097 and 13143), but they do not block the 
MET channel. We therefore tested whether any of  the 13 compounds blocked the slow outward K+ cur-
rent (IK,neo) that is expressed by early postnatal mouse OHCs and activates at potentials positive to –50 mV 
(35). OHCs were exposed to 30 μM of  each compound, and currents were elicited by applying a series of  
Figure 3. Effects of compounds (100 μM) on 
mouse cochlear hair cells in the absence of 
gentamicin. Cultures from P2 pups were treat-
ed for 48 hours with either (A) 1% DMSO (n = 2) 
or (B–N) 100 μM compound as indicated (n = 2 
for all compounds). Cultures were labeled with 
TRITC-phalloidin, and images were acquired 
from the basal coil. Asterisks identify com-
pounds that damage hair bundles, with arrows 
indicating examples of damaged bundles. 
Double asterisks identify compounds that were 
cytotoxic or caused loss of the sensory epithe-
lium. Scale bar: 50 μm.
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hyperpolarizing and depolarizing voltage steps from a holding potential of  –84 mV (Figure 6). Examples of  
currents recorded before, during, and after application of  3 of  the compounds, the Kv7 blockers 13097 and 
13143, and 13142, a compound that also blocked the MET channel, are shown in Figure 6, A, C, and E, 
along with the activation curves derived from the tail currents recorded before and during exposure (Figure 
6, B, D, and F). The average reduction in the maximum conductance (Gmax) of  IK,neo caused by each com-
pound and the distribution of  data are shown in Supplemental Table 2 and Figure 6G, respectively. Of  the 
13 compounds tested, only two (13170 and 13196) had no effect on IK,neo at a concentration 30 μM (Figure 
6G and Supplemental Table 2). The remaining 11 compounds, however, notably reduced IK,neo to varying 
degrees; these included linopirdine (13143), a compound that has previously been reported not to block 
IK,neo (35). The effects of  the compounds on the half  activation potential (V1/2) and the voltage sensitivity of  
activation (S) are listed in Supplemental Table 2. Most compounds did not change V1/2 or S significantly, 
suggesting a homogeneous block of  the ion channels underlying IK,neo.
Testing effects of  compounds on the antimicrobial efficacy of  gentamicin. The 13 compounds that protect 
OHCs from gentamicin-induced death were tested in a bacterial cell viability assay to identify whether 
any decrease the antibiotic activity of  gentamicin. The minimum inhibitory concentration (MIC, defined 
here as the minimum concentration of  gentamicin required to inhibit bacterial growth by ≥99%) of  
gentamicin was established for 3 circulating strains of  clinically relevant bacteria: Klebsiella pneumoniae, 
Pseudomonas aeruginosa, and Staphylococcus aureus. The bacteria were treated with gentamicin at the MIC 
(2.2 μM) together with each compound at 5 times the gentamicin MIC (11 μM). None of  the compounds 
resulted in a decrease in gentamicin activity (Supplemental Figure 5). When the experimental grouping 
structure was explicitly modeled as random effects (technical replicates nested within biological repli-
cates) using a mixed-effects model, two individual cases of  significant decreases in bacterial cell sur-
vival were identified [Pseudomonas aeruginosa, compound 13170, t11 = 2.90, P(FDR-adjusted) = 0.049; Klebsiella 
pneumoniae, compound 13228, t11 = 3.74, P(FDR-adjusted) = 0.002, where t11 is the degree of  freedom in a t 
distribution], but neither was found to be significant in more than one assay, and a significant decrease in 
bacterial cell survival was not identified in the Staphylococcus aureus assay.
Figure 4. Compounds providing protection against 5 μM gentamicin at low concentrations. Cultures prepared from P2 pups were treated with (A) 
0.5% DMSO (n = 67), (B) 5 μM gentamicin (n = 67), 5 μM gentamicin and 13143 at (C) 5 μM (n = 5), (E) 3 μM (n = 5), (G) 1 μM (n = 4), and (I) 0.5 μM (n = 
3) or 5 μM gentamicin and 13097 at (D) 30 nM (n = 5), (F) 10 nM (n = 5), (H) 3 nM (n = 4), and (J) 1 nM (n = 4) (numbers of independent tests are shown 
after each compound number). Cultures were labeled with TRITC-phalloidin. Images in A and B are representative of 67 experiments. Images in C–J are 
representative of 3–5 experiments. (K) Dose-response curves showing the percentage survival of basal-coil OHCs in cultures treated with gentamicin 
and either compound 13097 (red) or compound 13143 (blue) compared with that in control cultures. Error bars are SEM from 3–8 independent tests. 
Curves are fit to the equation: OHC survival (%) = B + (100–B)[C]/(K + [C]), where B is the percentage of OHCs surviving in gentamicin alone, [C] is the 
concentration of the compound, and K is the compound concentration at which 50% protection occurs. For 13097, K = 4.9 nM and B = 12.6%; for 13143, 
K = 840 nM and B = 11.5%. Scale bar: 50 μm.
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Candidate otoprotectants for cochlear OHCs and possible mechanisms of  action. The results described above 
suggest that 5 compounds (13097, 13142, 13143, 13154, and 13222) are candidate otoprotectants for 
high-frequency–encoding OHCs, protecting against 5 μM gentamicin at a concentration of  50 μM (or in 
some cases considerably less), not causing hair cell death or hair-bundle damage when tested alone at a 
concentration of  100 μM, and not inhibiting the antimicrobial action of  gentamicin. Three of  these com-
pounds (13142, 13154, and 13222) are MET channel blockers (Figure 5F and Supplemental Table 1) and 
may therefore prevent or reduce gentamicin entry via this route. All 5 block IK,neo (Figure 6G and Supple-
mental Table 1) and could potentially depolarize the OHCs and reduce the rate of  aminoglycoside loading 
by decreasing the driving force for entry via the MET channel.
To test whether any of  the 5 candidate otoprotectants would block or reduce the accumulation of  gen-
tamicin, we exposed mouse cochlear cultures to a low concentration of  GTTR in the presence of  a large 
molar excess of  each of  the compounds for a short period of  time. Compound 13170, a compound that 
blocks TR-Neo and FM 1-43FX loading in the zebrafish assays, was found to cause a considerable decrease 
in GTTR loading in OHCs (t7 = 9.66, P = 0.0001 using mixed-effects modeling) and was used as a positive 
control. A significant decrease (t7 = 4.15, P = 0.0043) in GTTR loading was seen in OHCs that were exposed 
to GTTR in the presence of  13143 but not in those exposed to GTTR in the presence of  13142 (t7 = 0.833, P 
= 0.43), 13097 (t7 = 0.883, P = 0.41), 13154 (t7 = 0.528, P = 0.61), or 13222 (t7 = 1.65, P = 0.14) (Figure 7).
Figure 5. Interactions of otoprotectants with the MET channel. Representative MET currents from OHCs in cultures prepared from P2 pups recorded 
before, during, and after exposure to (A) 50 μM 13143 (n = 12) and (B) 50 μM 13222 (n = 6). MET currents were recorded at membrane potentials from 
–164 mV to +96 mV in response to a sine-wave stimulus. Current-voltage curves for the peak MET currents derived from the recordings shown in A and 
B demonstrate (C) the lack of interaction of 13143 with the channel and (D) the voltage-dependence of block by 13222. (E) Fractional block of the MET 
currents at all membrane potentials reveals that 7 compounds, including 13143, do not interact with the channel. (F) Six compounds, including 13222, 
provide a voltage-dependent block that is in most cases strongest at moderately negative potentials. Error bars are SEM. Numbers of independent 
tests are shown after each compound number in graphs (E and F).
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To test whether cochlear hair cells could be 
protected by depolarization, elevated extracel-
lular K+ was used to depolarize the cells, and 
elevated extracellular Na+ was used to control 
for the increased osmolality. Hair cell numbers 
in medium containing an additional 18 mM of  
either NaCl (z = 0.71, P = 0.98) or KCl (z = 0.05, 
P > 0.99) were not significantly different from 
those seen in normal medium after 48 hours 
(Figure 8, A, C, E, and G), while a significant 
decrease was seen in the presence of  5 μM gen-
tamicin (z = 10.9, P < 0.001) (Figure 8, B and 
G). In cultures treated with 5 μM gentamicin in 
the presence of  an additional 18 mM NaCl (Fig-
ure 8D), hair cell loss was comparable to and 
not significantly different from that observed 
with 5 μM gentamicin in normal medium (z = 
0.12, P > 0.99) (Figure 8, B and G). In cultures 
treated with 5 μM gentamicin in the presence 
of  an additional 18 mM KCl (Figure 8F), there 
was a large and significant increase in hair cell 
numbers relative to those observed with 5 μM 
gentamicin in normal medium (z = 10.0, P < 
0.001) (Figure 8, B and G), although numbers 
were also significantly reduced relative to those 
observed in control medium without gentami-
cin (z = 3.8, P = 0.001) (Figure 8, A and G).
Although the results above provide evi-
dence that K+ depolarization can, as expect-
ed, provide protection against aminogly-
coside antibiotics, none of  the 5 candidate 
otoprotectants (13097, 13142, 13143, 13154, 
Figure 6. Interactions of otoprotectants with the 
basolateral potassium current IK,neo. Representative 
currents from OHCs in cultures prepared from P2 
pups were recorded before, during, and after expo-
sure to 30 μM (A) 13097, (C) 13142, and (E) 13143 (for 
the number of cells tested with each compound see 
G). Currents, averaged from 2 stimulus presenta-
tions, were recorded in response to 10 mV hyperpo-
larizing and depolarizing voltage steps from a hold-
ing potential of –84 mV. Schematic representations 
of the voltage step protocols are shown below each 
trace. Small leakage currents have been subtracted. 
(B, D, and F) Activation curves derived from the 
tail currents in A, C, and E before (black traces) and 
during (red traces) compound exposure. (G) Box-
and-whisker plot of maximum conductance (Gmax) 
as a percentage of control for all 13 otoprotective 
compounds: 13087 (n = 5), 13097 (n = 5), 13104 (n = 
7), 13142 (n = 6), 13143 (n = 7), 13150 (n = 2), 13154 (n 
= 4), 13170 (n = 7), 13190 (n = 5), 13196 (n = 5), 13218 
(n = 2), 13222 (n = 5), and 13228 (n = 3). Thick line = 
median; boxes = interquartile range (IQR). Whiskers 
extend an additional 1.5× IQR beyond the boxes. 
Outliers are shown as white circles. All recordings 
were performed at room temperature (20°C–23°C).
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and 13222) elicited a reduction in the resting mem-
brane potential when they were perfused onto OHCs 
under current clamp at a concentration of  30 μM (Fig-
ure 8, H–L). By contrast, perfusion with extracellular 
solution containing an additional 18 mM KCl caused 
a rapid depolarization of  15 ± 2.4 mV (±SEM; n = 10) 
of  the OHCs that reversed immediately upon washout 
(Figure 8M).
Zebrafish screen for compounds that protect against 
long-term gentamicin-induced damage. As 3 of  the com-
pounds that protect mouse cochlear hair cells against 
gentamicin did not protect zebrafish hair cells from 
neomycin, and as there are known differences in the 
mechanisms of  action of  gentamicin and neomycin in 
zebrafish hair cells (36), the 13 compounds proven to 
be effective in mouse cochlear cultures were retrospec-
tively retested in zebrafish using 10 μM gentamicin as 
the ototoxic agent. At 100 μM, 5 of  the compounds 
(13143, 13150, 13170, 13190, and 13228) consistently 
caused loss of  larval viability over the 5-hour time peri-
od of  the experiment. Of  the remaining 8 compounds, 
all showed protection against gentamicin damage (Fig-
ure 9). When the concentration of  the compounds was 
reduced to 50 μM, 3 compounds (13143, 13150, and 
13228) caused loss of  viability, 6 compounds (13087, 
13142, 13154, 13170, 13190, and 13196) showed par-
tial protection (Supplemental Figure 6, C, F, G, H, I, 
and J), and 4 compounds (13097, 13104, 13218, and 
13222) showed strong protection (Supplemental Figure 
6, D, E, K, and L).
Discussion
Using a combination of  zebrafish lateral line organs and 
mouse cochlear cultures as screening tools, we discovered 
13 compounds that protect or provide partial protection 
of  basal-coil mouse OHCs from gentamicin-induced cell 
death (Figure 10A). In the zebrafish assays, 2 of  the 13 
compounds reduced FM 1-43FX loading, 5 diminished 
TR-Neo labeling, and 10 provided protection from neo-
mycin-induced cell death. Notably, however, only 1 of  the 
Figure 7. Effects of lead otoprotectants on Texas red–conjugat-
ed gentamicin loading in mouse cochlear cultures. Represen-
tative (A, C, E, G, I, K, and M) DIC images and (B, D, F, H, J, L, 
and N) fluorescent images of cultures from P2 pups that were 
exposed to 0.2 μM GTTR for 10 minutes in presence of (A and B) 
1% DMSO (n = 21), (C and D) 100 μM 13097 (n = 5), (E and F) 100 
μM 13142 (n = 6), (G and H) 100 μM 13143 (n = 4), (I and J) 100 μM 
13154 (n = 3), (K and L) 100 μM 13170 (n = 6), and (M and N) 100 
μM 13222 (n = 6). Scale bar: 50 μm. (O) Box-and-whisker plot of 
background-corrected intensity values for fluorescence intensity 
in first-row OHCs in cultures exposed to GTTR in presence of 
DMSO, 13097, 13142, 13143, 13154, 13170, and 13222. Thick line 
= median; boxes = interquartile range (IQR). Whiskers extend 
an additional 1.5× IQR beyond the boxes. Outliers are shown as 
white circles. Scale bar: 50 μm.
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19 compounds that was effective in all 3 zebrafish assays protected mouse OHCs from gentamicin, and 10 
of  the 13 compounds that were successful in mouse cochlear cultures would have been detected using the 
neomycin-protection assay alone. The added value of  the TR-Neo–labeling and FM 1-43FX–loading assays 
for future large-scale screens is therefore questionable. A retrospective screen of  the 13 compounds that 
protect mouse cochlear hair cells in zebrafish using gentamicin rather than neomycin did not identify all of  
the compounds, as a subset consistently caused a loss of  larval viability over the longer duration required for 
the assay (5 hours for gentamicin as opposed to 1 hour for neomycin). Nonetheless, 4 of  the 5 lead otopro-
tectants (see below) would have been identified had the gentamicin assay been used for the primary selection.
Figure 8. Effects of elevated K+ and Na+ and effects of lead otoprotectants on resting membrane potential. (A–F) Cochlear cultures from P2 pups 
were grown in (A) control medium (n = 5) or (B) medium containing 5 μM gentamicin (n = 3), (C) 18 mM NaCl (n = 4), (D) 18 mM NaCl with 5 μM gen-
tamicin (n = 6), (E) 18 mM KCl (n = 4), and (F) 18 mM KCl with 5 μM gentamicin (n = 6). Cultures were labeled with antibodies to myosin 7a. Scale bar: 
50 μm. (G) Box-and-whisker plot showing numbers of OHCs remaining in the mid-basal region. Thick line = median; boxes = interquartile range (IQR). 
Whiskers extend an additional 1.5× IQR beyond the boxes. Outliers are shown as white circles. (H–M) Representative current clamp recordings of 
membrane potential in OHCs in cochlear cultures from P2 pups, obtained during and after superfusion with 30 μM of compounds as indicated and 18 
mM KCl. The addition of 18 mM KCl to the extracellular solution results in a rapid depolarization of the cell of approximately 15 mV that is reversible 
upon a return to normal KCl levels (n = 10). Exposing the cells to the otoprotectant compounds 13097 (n = 10), 13142 (n = 5), 13143 (n = 11), 13154 (n = 7), 
and 13222 (n = 7) has no effect on the resting membrane potential.
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Details of  the 13 compounds that prevented or attenuated gentamicin-induced death 
of  OHCs in mouse cochlear cultures are shown in Figure 10B. All have reached different 
stages of  preclinical and clinical development, and the majority have physicochemical 
properties that are ideal for oral absorption and potential passage through the blood-lab-
yrinth barrier (37). These include a MW of  <450 daltons, a cLogP of  <4, and a polar 
surface area of  <80 Å2. Of  the 13 compounds, 4 are known potassium channel blockers, 
4 are ionotropic glutamate receptor antagonists, and the other 5 belong to several differ-
ent classes of  agonists or antagonists. The fourth physicochemical property shown in 
Figure 10 is the pKa, a value that indicates the pH at which 50% of  the molecules will be 
ionized. There is a correlation between pKa and the ability of  the compound to interact 
with the MET channel, and all the positively charged compounds (pKa > 8.0), with the 
exception of  13196 and 13228, were able to block the MET channel to varying degrees. 
The other compounds (pKa < 6.0) are in a neutral form at physiological pH and did not 
block the MET current.
By excluding all compounds that caused significant hair-bundle damage when test-
ed alone at 100 μM and by selecting those that protect against 5 μM gentamicin at a 
concentration of  50 μM, 5 ion-channel inhibitors emerged as lead otoprotectants. These 
were 13142 [[±]-1-(1,2-diphenyl ethyl) piperidine] and 13222 (ifenprodil), NMDA 
receptor antagonists that also block both the MET current and IK,neo in early postnatal 
mouse cochlear hair cells; two inhibitors of  Kv7 channels (38), 13097 (XE991) and 13143 
(linopirdine) (32, 33, 39, 40), both of  which block IK,neo but not the hair cell MET current; 
and 13154, a selective antagonist of  the ATP-sensitive K+ channel Kir6 that blocks both 
the hair cell MET current and IK,neo. While all 5 compounds inhibit IK,neo, and although the 
results reveal K+ depolarization can provide protection from gentamicin, none of  them 
cause an immediate change in the resting membrane potential of  the OHCs, and none of  
them had an effect on the viability of  the hair cells in vitro over the course of  48 hours. It 
is unlikely, therefore, that interactions between the compounds and IK,neo determine their 
protective properties. The question therefore arises as to how these 5 compounds protect 
OHCs in mouse cochlear cultures.
Previous studies have indicated that aminoglycosides cause hair cell death by activat-
ing NMDA receptors and have shown that the NMDA modulators ifenprodil (13222), 
dizocilpine, and spermine limit aminoglycoside-induced hair cell loss in both rats and guinea pigs in vivo 
(41–43). While it has been unclear whether hair cell death is due to a direct effect on hair cells or due to 
an indirect effect via receptors present on the afferent fibers innervating the hair cells (44), a recent study in 
zebrafish has shown that excess glutamate signaling through ionotropic glutamate receptors induces hair cell 
death irrespective of  the presence or absence of  nerve fibers (45). Compounds 13142 and 13222 may there-
fore prevent aminoglycoside-induced hair cell death by blocking Ca2+ entry into hair cells via NMDA recep-
tors (41, 42, 46). Although 13142 and 13222 also block the hair cell MET channel and may therefore addi-
tionally provide protection by limiting aminoglycoside antibiotic entry, neither caused a significant reduction 
in GTTR loading, suggesting they either have a low affinity for the MET channel relative to GTTR or exert 
their otoprotective effects through the NMDA receptor.
Of  the remaining 3 compounds (13097, 13143, and 13154), compound 13143 (linopirdine) is the only 
one that reduces GTTR labeling. While this may explain why it provides protection, 13143 does not block 
the MET channel, suggesting its effects on GTTR loading are indirect. Compound 13097 (XE991) does not 
block the MET current or reduce GTTR labeling, suggesting that it acts downstream of  aminoglycoside 
entry. Although compound 13154 does block the MET channel, it does not reduce GTTR labeling, suggest-
ing that it also acts downstream of  aminoglycoside entry. As linopirdine and XE991 are known to block 
KCNQ4, a channel required for the survival of  mature OHCs (47, 48), and as the perfusion of  linopirdine 
Figure 9. Prevention of gentamicin-induced hair cell loss in zebrafish larvae with otoprotectants 
at a concentration of 100 μM. Zebrafish larvae (4 dpf) were treated for 5 hours with (A) E3 control, 
(B) 10 μM gentamicin, or (C–J) 10 μM gentamicin and 100 μM of compound as indicated. Neuro-
masts were prelabeled with 3 μM Yo-Pro-1. n = 3 independent experiments with 3 or more fish per 
well. Representative images of individual neuromasts shown. Scale bar: 25 μm.
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Figure 10. Summary of results and properties of compounds providing protection in mouse OHCs. (A) Proportional Venn diagram showing the number of 
compounds effective in the 3 zebrafish assays, with small circles identifying the compounds in each sector that were effective in the mouse OHCs. The 5 lead 
compounds are underlined. (B) Corresponding Venn numbers, identifier numbers, structure, commercial name, and known biological activity of the 13 com-
pounds found to protect mouse OHCs from gentamicin-induced damage at 50 μM. MW, a measure of lipophilicity (cLogP and cLogD), polar surface area (PSA), 
and pKa (pH at which the compound is 50% ionized) for compounds are also included. Thick black lines separate compounds of differing biological activity.
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into the inner ear leads to the loss of  cochlear OHCs (49), these compounds would require modification 
to provide otoprotectants for use in mature animals. KCNQ4 is not, however, expressed in early postnatal 
hair cells (35), and XE991 protects at a concentration below its IC50 for KCNQ4 in mature inner hair cells, 
which is estimated to be 30 nM (assuming a Hill coefficient of  1) (50), providing further evidence it is acting 
downstream of  aminoglycoside entry.
The results identify 5 lead compounds that can be used to inform the development of  drugs for pro-
tecting sensory hair cells in the mammalian inner ear from the toxic side effects of  the aminoglycoside 
antibiotics. This more than doubles the number already identified as being wholly or partially effective 
in mouse hair cells using a similar approach, i.e., preselection using zebrafish lateral line neuromasts 
(16–23), proving the value of  this strategy and providing additional reagents that will help solve an 
ever-increasing clinical issue.
Methods
Compound library
A Tocriscreen Custom Collection Ion Channel Set of  160 biologically active compounds (ion-channel 
activators and inhibitors supplied predissolved as 10 mM stock solutions in DMSO) was obtained from 
Tocris. Molecules effective in one or more of  the initial screens were confirmed by testing new stocks 
from Tocris, HelloBio, and MilliporeSigma. Purity was >95%, and compounds were used without further 
purification. Physicochemical properties were calculated using MarvinSketch 16.8.15.0 by ChemAxon 
(https://www.chemaxon.com). Chemical structures were drawn using ChemDraw Prime 15.0.
Zebrafish assays
Zebrafish embryos were obtained from sibling crosses of  adult nacre (mifta–/–) fish (51) either housed at or 
obtained from the University of  Sheffield. The nacre strain has reduced numbers of  pigmented melano-
phores and was used for the screens involving fluorescent compounds, as levels of  pigmentation are sub-
stantially reduced and signal detection is thus improved. The development of  lateral line neuromasts and 
hair cells in this strain appears normal (for examples, see Figure 1A and Supplemental Figure 1). Larvae at 
4 dpf  were dispensed into 96-well microtiter plates at a density of  3–4 per well. For the FM 1-43 dye-load-
ing assay, larvae were incubated in 100 μM compound (total volume of  100 μl) at room temperature for 10 
minutes, exposed to 3 μM FM 1-43FX (Life Sciences, F35355) for 1 minute, washed, and then anesthetized 
with 0.025% MS222 (MilliporeSigma E10521). Wells containing larvae were imaged at ×4 magnification 
using the Phenosight imaging system (Ash Biotech), and larvae were scored for presence or absence of  
fluorescently labeled neuromasts. If  the larvae only had a small proportion of  neuromasts (e.g., only 3 
terminal neuromasts or just the head neuromasts, see Figure 1A) labeled, the compound was described as a 
weak blocker. A compound was considered toxic if  there was loss of  viability or the fish became fluorescent 
and neuromasts could not be detected above background (Figure 1C). For the TR-Neo screen, larvae were 
incubated in 100 μM compound and exposed to 25 μM TR-Neo for 90 seconds, washed, and anesthetized. 
Entire larvae were imaged and scored for presence or absence of  labeled neuromasts with a ×16 objective 
on a Zeiss IM-35 inverted microscope. The trunk neuromasts 3–9 were assayed for presence or absence of  
fluorescence with a ×40 objective. A compound was designated as a weak blocker if  fluorescence was only 
detected at ×40. The neomycin-protection and gentamicin screen were performed as described previously 
(26). Briefly, Yo-Pro-1 (Invitrogen, Y3603) (29) prelabeled larvae were incubated in 25 μM test compound 
with 6.25 μM neomycin sulphate for 1 hour or 50 or 100 μM test compound with 10 μM gentamicin sul-
phate (MilliporeSigma, G3632) for 5 hours. Plates were screened using a ×16 objective. Trunk neuromasts 
3–9 were viewed and assessed as described previously (26).
Mouse cochlear culture protection assay
Mouse pups of  either sex were obtained from a colony of  outbred CD1 mice that was maintained at the 
University of  Sussex with stock originally obtained from Charles River. Cochlear cultures were prepared 
from pups at P2 as described previously (26, 52) and, after 1 day in vitro, were treated with 50 μM test 
compound and 5 μM gentamicin sulphate (MilliporeSigma, G3632) or augmented levels of  extracellu-
lar Na+ or K+ and 5 μM gentamicin sulphate for a further 48 hours before fixation and staining with 
TRITC-phalloidin (MilliporeSigma, P1951) or double labeling with Texas red–conjugated phalloidin 
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(Invitrogen) and anti-myosin7a (Proteus, 25-6790). Cultures were imaged with a Zeiss Axioplan2 micro-
scope. Compounds that did not provide protection were discarded, and no further tests were run on them. 
Those providing protection were retested at varying concentrations. For details of  the analysis of  hair cell 
survival/protection, see the Supplemental Methods.
Electrophysiology
MET currents and basolateral potassium currents were recorded from OHCs in cochlear cultures that had 
been prepared from P2 pups and maintained for 1 or 2 days in vitro as previously described (26). For full 
details, see the Supplemental Methods.
GTTR-loading assay in mouse cochlear cultures
Mouse cochlear cultures were treated with 1% DMSO or 100 μM test compound for 5 minutes, GTTR 
(obtained from P.S. Steyger, Oregon Hearing Research Center, Oregon Health & Science University, Port-
land, Oregon, USA) was added to a final concentration of  0.2 μM for a further 10 minutes, and cultures 
were washed 3 times. Images were captured at a fixed distance from the basal end of  the explant 10 minutes 
after the onset of  GTTR washout. Each compound was tested on a minimum of  3 different cultures, and 
a similar number of  DMSO controls were included in each experiment. Intensity values were obtained 
from 40 × 40 pixel regions of  interest in 10 adjacent first-row OHCs. Analysis was as follows: 10 technical 
replicates (cells) were nested within 3–5 biological replicates for each compound or the 1% DMSO control. 
Background-corrected intensity values were natural logarithm-transformed as ln(data + 1) and analyzed 
using mixed-effects models, assuming normal error distributions. For full details of  analysis, see Statistics.
Statistics
Electrophysiology. Potassium current activation curve data were analyzed for V1/2 and S by 2-tailed paired 
t test using Graphpad QuickCalcs online software. Gmax was analyzed by performing a 1-sample t test 
(2-tailed testing) using GraphPad InStat v3.10, assigning statistical significance at P < 0.05. For additional 
information, see the Supplemental Methods.
The GTTR-loading assay in mouse cochlear cultures, the mouse cochlear culture protection assay 
and antimicrobial susceptibility testing were analyzed using R 3.2.2 (53) with the ‘lme4’ package and are 
detailed below.
GTTR-loading assay in mouse cochlear cultures. GTTR loading was analyzed using mixed-effects models, 
assuming normal error distributions. The compound applied was fitted as a categorical fixed effect, and the 
experimental design of  hierarchical replication for each compound, grouped by day, was fitted as random 
effects. Within this modeling framework, each compound was compared with 1% DMSO control values 
using 2-tailed t tests, assigning statistical significance at P < 0.05.
Mouse cochlear culture protection assay. The effects of  gentamicin, NaCl, and KCl on hair cell survival 
were modeled using generalized linear mixed-effects models, assuming Poisson-distributed errors and log 
link functions. Explanatory variables were fitted as interacting categorical fixed effects. Variability between 
replicate measurements on each cochlea, nested within variability between observers, was modeled as ran-
dom effects. Pairwise comparisons among all combinations of  interacting fixed effects were quantified 
using Tukey honestly significant difference post-hoc tests, assigning statistical significance at P < 0.05.
Bacterial growth conditions and antimicrobial susceptibility testing. Antimicrobial susceptibility testing was 
analyzed using mixed-effects models, assuming normal error distributions. Log10-transformed lumines-
cence was modeled as the response variable. Compound identity (including compound-free control) was 
fitted as a single categorical explanatory variable. Technical replication, nested within biological variation, 
was fitted as random effects. Pairwise contrasts, comparing each compound to the control, were assessed. 
Adjusted P values were produced using the Benjamini-Hochberg false discovery rate method, assigning 
statistical significance at P < 0.05.
Study approval
Animals were raised as per Home Office guidelines, and all experiments were in accordance with the Home 
Office Animals (Scientific Procedures) Act 1986 and were performed with approval of  the Animal Welfare 
and Ethical Review Boards at the Universities of  Sussex and Sheffield.
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